Today ClinOne announced a strategic partnership with CQuentia to bring focused and personalized molecular testing to clinical trial patients. ClinOne’s mission is to simplify and accelerate clinical trials for those conducting, participating in and benefiting from clinical studies in onsite, remote, and strictly virtual settings. “Our goal is to increase patient access to life changing clinical trials, while continually analyzing operations and developing workflows and capabilities to minimize our clients’ costs,” explains Rob Bohacs, ClinOne’s CEO. Partnering with a laboratory such as CQuentia, provides a depth of diagnostic testing that expands ClinOne’s offering and brings comprehensive lab solutions directly to the patients.
ClinOne continuously evaluates the market for innovative companies and products to add to its suite of e-clinical technologies. “CQuentia is a thought leader in genomic testing and a natural fit, given their comprehensive COVID-19 testing capabilities offered at or near patients’ homes,” explains Dr. Elizabeth Esterl, ClinOne’s VP of Operations and Research.
CQuentia is a next-generation sequencing FDA CLIA laboratory and data service that brings a sophisticated precision medicine platform to ClinOne’s suite of resources. Among the tests conducted by CQuentia and made available through ClinOne are COVID-19 RT-PCR and Antibody tests, Respiratory Pathogen Panel (RPP) and Pharmacogenomic testing (PGx). CQuentia’s testing improves the overall well-being of patients by reducing risk and enhancing safety protocols. Esterl explains that “such actionable and customized clinical information aligns with our clients to expand virtual clinical trials, by enhancing screening, increasing enrollment and keeping participants actively engaged throughout the trial period.”
“What separates CQuentia from other testing laboratories is our platform agnostic approach to deliver solutions and our ability to create personalize client specific reports and alerts which plays to ClinOne’s strengths and uniqueness as they bring mission-critical clinical study details to clients, research sites and patients. We are motivated by the change we can make in people’s lives through this collaboration, “ explains Alan Meeker, CQuentia CEO.
ClinOne is a suite of technologies created to improve access to mission-critical clinical study details, manage research site workflow, and provide patients with a solution to manage the clinical trial journey. The company’s sole mission is to simplify and accelerate clinical trials through a single, unified central clinical trial operating system between sponsors, research sites and patients. Today, 45 global sponsors and 2,000 research institutions across 55 countries rely on ClinOne’s technology. For more information visit www.clinone.com.
CQuentia is a privately-held molecular testing and sequencing laboratory, positioned to provide doctors, governments, hospitals, payers and employers with rapid, reliable results. CQuentia provides precision medicine, data banking and infection identification, thus enabling clients to make informed clinical decisions, improve outcomes and deliver overall value throughout the healthcare continuum. For more information please visit www.cquentia.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005741/en/